Bradley J. Monk
Gynaecologic oncologist who co-led KEYNOTE-826, innovaTV 301 and KEYNOTE-A18, the trials that rebuilt cervical cancer treatment.
Overview
Bradley Monk (GOG Partners) was a lead investigator of GOG 240, which established bevacizumab in advanced cervical cancer, and co-led KEYNOTE-826, innovaTV 301 (tisotumab vedotin) and KEYNOTE-A18, together the three practice-changing cervical cancer trials of the past five years. He co-leads the GOG Partners industry-collaboration programme and has led ovarian PARP inhibitor trials including ATHENA.
Pages like this
not linked directly; found by shared links- PersonIgnace Vergote
Shares innovaTV 301 / ENGOT-cx12 / GOG-3057, Tissue factor, Tisotumab vedotin, Cervical cancer and the tags cervical, ovarian, cooperative-group.
- PersonNicoletta Colombo
Shares KEYNOTE-826, VEGF / VEGFR, Cervical cancer, Pembrolizumab and the tag cervical.
- PersonDomenica Lorusso
Shares KEYNOTE-A18 / ENGOT-cx11 / GOG-3047, Cervical cancer, Pembrolizumab, PD-1 and the tag cervical.
- PersonAndreas du Bois
Shares Ovarian cancer and the tags ovarian, cooperative-group.
- PersonLinda Mileshkin
Shares Cervical cancer and the tags cervical, cooperative-group.
- PersonRobert L. Coleman
Shares VEGF / VEGFR, Ovarian cancer and the tag ovarian.
- PersonSébastien Armanet
Shares Cervical cancer, Ovarian cancer and the tag cooperative-group.
- PersonMansoor Raza Mirza
Shares PD-1, Ovarian cancer, Immune checkpoint inhibitors and the tag ovarian.